All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Jazz Pharmaceuticals plc's acquisition of Redx Pharma plc's pan-RAF inhibitor program for treating RAF- and RAS-mutant tumors was rocket fuel for Redx's stock (AIM:REDX), which closed 108% higher than it opened, offering some relief for the struggling company.